Sarbanes: Diversity is Central to Biomedical Research [VIDEO]
WASHINGTON, D.C. – Subcommittee on Health Vice Chair Representative John Sarbanes (D-Md.) focused on improving diversity in clinical trials and biomedical research as central to developing a deeper understanding of various diseases and how to treat them.
In the Energy and Commerce Committee’s Health Subcommittee hearing, “The Future of Biomedicine: Translating Biomedical Research Into Personalized Health Care,” Congressman Sarbanes asked experts to speak about the need for greater inclusion of underrepresented groups in biomedical research. Diversity, he pointed out, can further our knowledge of differences within certain types of debilitating and deadly diseases and hold great promise for the future of treatments.
“Like all of us, I hear from constituents about the need to fund and advance research on a variety of diseases – whether it’s cancer, diabetes or other diseases – and what we can do to detect, treat and cure diseases and improve the quality of life for our families and communities,” said Congressman Sarbanes.
He continued, “I also bring the perspective of being an original cosponsor of a critical bill, the Henrietta Lacks Enhancing Cancer Research Act, which as you know directed the Government Accountability Office (GAO) to complete a study and provide recommendations on how federal agencies can address barriers to participation for underrepresented populations in federally funded cancer clinical trials. This bill became law earlier this year.”
See below for a video of the Congressman’s full remarks.